Skip to content

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01655043
Enrollment
20
Registered
2012-08-01
Start date
2012-09-30
Completion date
2014-02-28
Last updated
2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia

Keywords

Magnetic Resonance Imaging, regadenoson

Brief summary

Coronary artery disease (CAD, coronary heart disease) is the leading cause of death in the U.S., causing 1 in 5 deaths in 2005. The current method for diagnosing coronary artery disease that is considered most accurate is coronary angiography however it involves risk and radiation. Alternatively nuclear imaging test and MRI stress test only permits the semi qualitative analysis of the myocardial perfusion images. In this proposal the investigators will develop a means to calculate Coronary Flow Reserve (CFR) using the MRI. the investigators approach has the potential to reduce mortality from myocardial infarction by effecting a change in the patient management paradigm. Absolute quantification of myocardial perfusion will detect coronary stenosis and CAD in patients with more accuracy than the semi-quantitative or qualitative analysis of perfusion images. Measurement of Coronary Flow Reserve is important for the following reasons: decrease of coronary flow reserve has been identified as a first effect of CAD; it provides an objective measure of treatment efficacy. The purpose of this study is to compare images from nuclear stress test and/or coronary angiography with Magnetic Resonance Imaging (MRI) that will evaluate subjects with coronary artery disease calculating myocardial blood flow using a novel MRI technique combined to an extracellular Gadolinium-based contrast agent and stressor agent

Detailed description

The main hypothesis the investigators will test is that changes in myocardial blood volume, under physiologic stress, correlate with myocardial flow reserve as measured in low spatial resolution nuclear SPECT scans. Secondary hypothesis is that stress perfusion as quantified with bolus height corrected gadofosveset trisodium images, better correlate with SPECT perfusion than uncorrected, relative perfusion values. The investigators propose implementing the scan protocol using a 1.5T or 3.0T MRI scanner. The investigators will scan a series of 20 patients recruited from the nuclear stress lab at Northwestern Memorial Hospital. These subjects will be approached and enrolled into a HIPPA Compliant, IRB approved research study to assess the effectiveness of myocardial perfusion and blood volume images to measure myocardial blood volume. Subjects will be scanned with a modified version of the clinical stress-perfusion protocol. Correlation analysis will be used to test the hypothesis that quantitative blood volume is an indicator of myocardial flow reserve.

Interventions

DRUGRegadenoson

Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.

DRUGgadofoveset trisodium

All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.

Sponsors

Astellas Pharma Global Development, Inc.
CollaboratorINDUSTRY
Northwestern University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
19 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

Under an Institutional Committee on Human Research board approved protocol, 20 patients with a suspected myocardial ischemic disease with positive stress nuclear medicine test laboratory will be recruited in this prospective study. All subjects will be screened for GFR within 24 hours before the exam. All patients must have a GFR \> 30 mL/min/1.73m2 to be included in the study. All subjects will be selected following the Nephrogenic Systemic Fibrosis (NSF) guidelines. All dialysis patients or end-stage renal disease patients with a creatinine clearance of \< 30mL/min will not be selected for the study to avoid NSF.

Exclusion criteria

1. Age 18 to 89 years; 2. Known contraindication to MR imaging (such as pacemaker placement, magnetic implants, etc); 3. Claustrophobia; 4. Inability to perform an adequate breath-hold for imaging, 5. Inability to provide informed consent; 6. all subjects will be will be screened for GFR within 24 hours before the exam and subjects presenting with GFR \< 60 ml/min will be excluded; 7. Pregnant and lactating women; 8. Patients with hypersensitivity to gadolinium contrast agents, metoprolol, adenosine, or nitroglycerin; 10\) Contra indication for Regadenoson 1. 2nd- or 3rd-degree AV block (except in patients with a functioning artificial pacemaker) 2. Sinus node disease (except in patients with a functioning artificial pacemaker) 3. Unstable angina 4. Acute myocardial infarction 5. Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) 6. Hypersensitivity to adenosine 7. Caffeine within 12-24 hours 8. Theophylline and Dipyridamole products within 24 hours

Design outcomes

Primary

MeasureTime frameDescription
Quantification of Myocardial Blood Volumeoutcome measured following single MRI scanThe investigators anticipated that a novel MRI imaging protocol using a high relaxivity blood-pool contrast agent (gadofosveset trisodium) would be capable of quantifying coronary flow reserve based on quantification of myocardial blood volume and would be correlated with myocardial flow reserve as measured in low spatial resolution nuclear SPECT scans. Pre- and post- gadofosveset trisodium images were to be used to calculate the myocardial blood volume. Myocardial blood volume is derived from an equation of the relaxation times of hydrogen atoms in the blood and myocardium. If the agent administered did not behave as a true intravascular agent in the myocardium, quantification of myocardial intravascular blood volume (and hence a calculated coronary flow reserve) could not be calculated using the specified approach. In this case, relaxation times would be reported. Relaxation (R) times are measured in inverse seconds.

Countries

United States

Participant flow

Participants by arm

ArmCount
Coronary Artery Disease Patients
Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
20
Total20

Baseline characteristics

CharacteristicCoronary Artery Disease Patients
Age, Continuous61.8 years
STANDARD_DEVIATION 12.2
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
15 Participants
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
7 Participants
Sex: Female, Male
Male
13 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Quantification of Myocardial Blood Volume

The investigators anticipated that a novel MRI imaging protocol using a high relaxivity blood-pool contrast agent (gadofosveset trisodium) would be capable of quantifying coronary flow reserve based on quantification of myocardial blood volume and would be correlated with myocardial flow reserve as measured in low spatial resolution nuclear SPECT scans. Pre- and post- gadofosveset trisodium images were to be used to calculate the myocardial blood volume. Myocardial blood volume is derived from an equation of the relaxation times of hydrogen atoms in the blood and myocardium. If the agent administered did not behave as a true intravascular agent in the myocardium, quantification of myocardial intravascular blood volume (and hence a calculated coronary flow reserve) could not be calculated using the specified approach. In this case, relaxation times would be reported. Relaxation (R) times are measured in inverse seconds.

Time frame: outcome measured following single MRI scan

ArmMeasureGroupValue (MEAN)Dispersion
Coronary Artery Disease PatientsQuantification of Myocardial Blood VolumeDelta R1(blood)3.63 seconds^-1Standard Deviation 0.54
Coronary Artery Disease PatientsQuantification of Myocardial Blood VolumeDelta R1(myo)1.23 seconds^-1Standard Deviation 0.24

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026